Akeso
Clinical trials sponsored by Akeso, explained in plain language.
Akeso
9926
HKEX
Chinese biopharma developing antibody drugs for cancer and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy men to test cancer Drug's new recipe Results expected Sep 2026 (estimated)
- New allergy drug AK139 aims to stop sneezing and stuffy noses Results expected Sep 2026 (estimated)
- New drug combo aims to fight bile duct cancer Results expected Oct 2026 (estimated)
- New cancer drug AK138D1 enters first human trial Results expected Oct 2026 (estimated)
- New cancer drug targets two proteins at once in early trial Results expected Nov 2026 (estimated)